MLH1 Inhibitors
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin inhibits MLH1 indirectly by modulating the NF-κB pathway. It suppresses IκB kinase, preventing NF-κB activation. This inhibition downregulates genes involved in DNA repair, including MLH1. Curcumin's impact on the NF-κB pathway influences MLH1 expression, potentially affecting DNA mismatch repair processes. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A acts as an indirect MLH1 inhibitor by targeting histone deacetylases (HDACs). By inhibiting HDACs, it alters chromatin structure, impacting gene expression. In particular, Trichostatin A-induced histone modifications may affect MLH1 transcription, implicating epigenetic regulation in the modulation of DNA mismatch repair mechanisms. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
5-Aza-2'-deoxycytidine, a DNA demethylating agent, indirectly influences MLH1. It inhibits DNA methyltransferases, leading to DNA demethylation. MLH1 promoter hypermethylation is a common mechanism of MLH1 inactivation in cancers. By demethylating the MLH1 promoter, this compound can potentially restore MLH1 expression, promoting DNA mismatch repair functionality. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Cisplatin indirectly affects MLH1 by inducing DNA damage. As a platinum-based chemotherapeutic, it forms intrastrand crosslinks in DNA, triggering cellular responses. MLH1 expression may be influenced as a part of DNA damage response pathways. Cisplatin's impact on DNA structure can modulate MLH1 levels, potentially affecting the cellular capacity for DNA mismatch repair. | ||||||
Sulindac | 38194-50-2 | sc-202823 sc-202823A sc-202823B | 1 g 5 g 10 g | $32.00 $86.00 $150.00 | 3 | |
Sulindac, a non-steroidal anti-inflammatory drug, indirectly modulates MLH1 through inhibition of the Wnt/β-catenin pathway. It targets cyclooxygenases, disrupting Wnt signaling. As MLH1 is a downstream target of Wnt, Sulindac's interference with this pathway can affect MLH1 expression, revealing a link between inflammatory pathways and DNA mismatch repair regulation. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
Etoposide indirectly influences MLH1 by inducing DNA damage. As a topoisomerase II inhibitor, it promotes DNA strand breaks, activating DNA damage response pathways. MLH1 expression can be modulated as part of the cellular response to DNA damage. Etoposide's impact on DNA integrity may contribute to alterations in MLH1 levels, affecting DNA mismatch repair processes. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
Sodium butyrate indirectly inhibits MLH1 by targeting histone deacetylases (HDACs). It enhances histone acetylation, affecting chromatin structure and gene expression. MLH1, being sensitive to epigenetic modifications, can experience altered transcription in response to sodium butyrate. The compound's influence on HDACs provides a route for epigenetic modulation of MLH1 expression. | ||||||
2′-Deoxy-2′,2′-difluorocytidine | 95058-81-4 | sc-275523 sc-275523A | 1 g 5 g | $56.00 $128.00 | ||
Gemcitabine indirectly affects MLH1 by inducing DNA damage. As a nucleoside analog, it incorporates into DNA, leading to chain termination and DNA damage. MLH1 expression may be influenced as part of the cellular response to damaged DNA. Gemcitabine's impact on DNA structure and replication can modulate MLH1 levels, potentially impacting DNA mismatch repair mechanisms. | ||||||
Oxaliplatin | 61825-94-3 | sc-202270 sc-202270A | 5 mg 25 mg | $112.00 $394.00 | 8 | |
Oxaliplatin indirectly influences MLH1 by inducing DNA damage. As a platinum-based chemotherapeutic, it forms DNA adducts, activating cellular responses. MLH1 expression may be modulated as part of the DNA damage response pathways. Oxaliplatin's impact on DNA integrity can affect MLH1 levels, potentially influencing the cellular capacity for DNA mismatch repair. | ||||||
6-Mercaptopurine | 50-44-2 | sc-361087 sc-361087A | 50 mg 100 mg | $72.00 $104.00 | ||
6-Mercaptopurine indirectly modulates MLH1 by interfering with purine metabolism. It is incorporated into DNA, disrupting nucleotide synthesis. MLH1 expression can be influenced as part of the cellular response to altered DNA metabolism. 6-Mercaptopurine's impact on DNA structure and synthesis may contribute to changes in MLH1 levels, potentially affecting DNA mismatch repair processes. | ||||||